Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.
Also called NCT03486561
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Sponsor
- OBS Pakistan
- Registry
-
NCT03486561
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03486561. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-01 (anticipated); primary completion 2018-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
- Acronym
- MIDA
- Condition
- Chronic Stable Angina
- Intervention (Drug)
- Ranolazine
- Lead sponsor
- OBS Pakistan
Record details
- Record id
cardio:ct-nct03486561- Content hash
bf3b4c8f8f08380a248ed443649a3c5c358c01c4064ce2da9233f3ba51e611a1